↓ Skip to main content

Pathobiology and management of prostate cancer-induced bone pain: recent insights and future treatments

Overview of attention for article published in Inflammopharmacology, August 2013
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age
  • Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter
1 X user
peer_reviews
1 peer review site
reddit
1 Redditor

Citations

dimensions_citation
38 Dimensions

Readers on

mendeley
81 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Pathobiology and management of prostate cancer-induced bone pain: recent insights and future treatments
Published in
Inflammopharmacology, August 2013
DOI 10.1007/s10787-013-0183-7
Pubmed ID
Authors

Arjun Muralidharan, Maree T. Smith

Abstract

Prostate cancer (PCa) has a high propensity for metastasis to bone. Despite the availability of multiple treatment options for relief of PCa-induced bone pain (PCIBP), satisfactory relief of intractable pain in patients with advanced bony metastases is challenging for the clinicians because currently available analgesic drugs are often limited by poor efficacy and/or dose-limiting side effects. Rodent models developed in the past decade show that the pathobiology of PCIBP comprises elements of inflammatory, neuropathic and ischemic pain arising from ectopic sprouting and sensitization of sensory nerve fibres within PCa-invaded bones. In addition, at the cellular level, PCIBP is underpinned by dynamic cross talk between metastatic PCa cells, cellular components of the bone matrix, factors associated with the bone microenvironment as well as peripheral components of the somatosensory system. These insights are aligned with the clinical management of PCIBP involving use of a multimodal treatment approach comprising analgesic agents (opioids, NSAIDs), radiotherapy, radioisotopes, cancer chemotherapy agents and bisphosphonates. However, a major drawback of most rodent models of PCIBP is their short-term applicability due to ethical concerns. Thus, it has been difficult to gain insight into the mal(adaptive) neuroplastic changes occurring at multiple levels of the somatosensory system that likely contribute to intractable pain at the advanced stages of metastatic disease. Specifically, the functional responsiveness of noxious circuitry as well as the neurochemical signature of a broad array of pro-hyperalgesic mediators in the dorsal root ganglia and spinal cord of rodent models of PCIBP is relatively poorly characterized. Hence, recent work from our laboratory to develop a protocol for an optimized rat model of PCIBP will enable these knowledge gaps to be addressed as well as identification of novel targets for drug discovery programs aimed at producing new analgesics for the improved relief of intractable PCIBP.

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 81 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Malaysia 1 1%
Netherlands 1 1%
Italy 1 1%
Argentina 1 1%
Denmark 1 1%
Unknown 76 94%

Demographic breakdown

Readers by professional status Count As %
Researcher 13 16%
Student > Ph. D. Student 11 14%
Other 9 11%
Student > Bachelor 8 10%
Student > Doctoral Student 7 9%
Other 20 25%
Unknown 13 16%
Readers by discipline Count As %
Medicine and Dentistry 32 40%
Agricultural and Biological Sciences 8 10%
Pharmacology, Toxicology and Pharmaceutical Science 5 6%
Biochemistry, Genetics and Molecular Biology 4 5%
Business, Management and Accounting 3 4%
Other 10 12%
Unknown 19 23%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 26 May 2014.
All research outputs
#14,182,545
of 22,731,677 outputs
Outputs from Inflammopharmacology
#276
of 533 outputs
Outputs of similar age
#111,001
of 197,251 outputs
Outputs of similar age from Inflammopharmacology
#2
of 5 outputs
Altmetric has tracked 22,731,677 research outputs across all sources so far. This one is in the 35th percentile – i.e., 35% of other outputs scored the same or lower than it.
So far Altmetric has tracked 533 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.5. This one is in the 45th percentile – i.e., 45% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 197,251 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 41st percentile – i.e., 41% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 5 others from the same source and published within six weeks on either side of this one. This one has scored higher than 3 of them.